

Ready to start planning your care? Call us at [646-926-0945](tel:646-926-0945) to make an appointment.

×



Memorial Sloan Kettering  
Cancer Center

[Make an Appointment](#)

[Back](#)

[About Us](#) [Mission & Treatment](#)

[About Cancer & Treatment](#)

What can we help you find today?

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

FOR THE MEDIA



Lab Phone  
646-888-4058

Email  
[robsonm@mskcc.org](mailto:robsonm@mskcc.org)

My research is focused on the best ways to use genetic information to improve outcomes of patients with or at risk for hereditary cancers of all types. This includes the integration of genetic testing for both common and rare variants into clinical management, as well as evaluation of the clinical usefulness of genome-wide association studies.

I have played an active role in investigating and assessing cancer risks associated with *BRCA* mutations, especially those associated with breast and ovarian cancer, and conducting studies to define the clinical behavior and optimal management of individuals carrying *BRCA* mutations.

I also participate in the development of new treatments, such as PARP inhibitors, which may be particularly useful in people with *BRCA* mutations.

## My Videos

- [The Inaugural BRCA 2021: Patient Symposium on Hereditary Breast and Ovarian Cancer](#)

## Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Mark E. Robson discloses the following relationships and financial interests:

- Artios Pharma Limited  
Professional Services and Activities (Uncompensated)
- AstraZeneca

- Professional Services and Activities (Uncompensated)
- Clinical Care Options
  - Professional Services and Activities
- Foundation Medicine
  - Professional Services and Activities (Uncompensated)
- Integrity Continuing Education, Inc.
  - Professional Services and Activities
  
- Medical Educator Consortium, Inc.
  - Professional Services and Activities
- MJH Associates
  - Professional Services and Activities
- myMedEd, Inc.
  - Professional Services and Activities
- Research to Practice
  - Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

---

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#) . For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at [ecoi@mskcc.org](mailto:ecoi@mskcc.org) .

[View all disclosures \(https://www.mskcc.org/disclosures\)](https://www.mskcc.org/disclosures)

© 2026 Memorial Sloan Kettering Cancer Center